190 related articles for article (PubMed ID: 22074588)
1. Better targeting melanoma: options beyond surgery and conventional chemotherapy.
Kyrgidis A; Valasidis A; Bourlidou E; Andreadis C
Recent Pat Endocr Metab Immune Drug Discov; 2011 May; 5(2):147-59. PubMed ID: 22074588
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic options in the medical management of advanced melanoma.
Lutzky J
Semin Cutan Med Surg; 2010 Dec; 29(4):249-57. PubMed ID: 21277538
[TBL] [Abstract][Full Text] [Related]
3. Current advances and perspectives in the treatment of advanced melanoma.
Livingstone E; Zimmer L; Vaubel J; Schadendorf D
J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment of malignant melanoma.
Mota A; Deisseroth A
Clin Plast Surg; 2000 Jul; 27(3):463-74, x. PubMed ID: 10941566
[TBL] [Abstract][Full Text] [Related]
5. [Systemic therapy for malignant melanoma].
Rudolph BM; Groffik A; Stanger C; Loquai C; Grabbe S
Hautarzt; 2012 Nov; 63(11):885-98. PubMed ID: 23114509
[TBL] [Abstract][Full Text] [Related]
6. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulators for skin cancer.
Villa AM; Berman B
J Drugs Dermatol; 2004; 3(5):533-9. PubMed ID: 15552605
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-mediated drug delivery for treating melanoma.
Mundra V; Li W; Mahato RI
Nanomedicine (Lond); 2015; 10(16):2613-33. PubMed ID: 26244818
[TBL] [Abstract][Full Text] [Related]
9. Towards new therapeutic approaches for malignant melanoma.
Pacheco I; Buzea C; Tron V
Expert Rev Mol Med; 2011 Nov; 13():e33. PubMed ID: 22044938
[TBL] [Abstract][Full Text] [Related]
10. Novel Nanolipoidal Systems for the Management of Skin Cancer.
Singh A; Nimisha
Recent Pat Drug Deliv Formul; 2020; 14(2):108-125. PubMed ID: 32807069
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
Di Giacomo AM; Margolin K
Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
[TBL] [Abstract][Full Text] [Related]
12. Node positive melanoma--a positive note?
Kelly J; Kerin MJ
Surgeon; 2012 Apr; 10(2):63-4. PubMed ID: 22385525
[No Abstract] [Full Text] [Related]
13. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for advanced malignant melanoma.
Buzaid AC; Murren J
Int J Clin Lab Res; 1992; 21(3):205-9. PubMed ID: 1591369
[TBL] [Abstract][Full Text] [Related]
15. Melanoma: chemotherapy.
Lee SM; Betticher DC; Thatcher N
Br Med Bull; 1995 Jul; 51(3):609-30. PubMed ID: 7552084
[TBL] [Abstract][Full Text] [Related]
16. A review on liposome-based therapeutic approaches against malignant melanoma.
Mirzavi F; Barati M; Soleimani A; Vakili-Ghartavol R; Jaafari MR; Soukhtanloo M
Int J Pharm; 2021 Apr; 599():120413. PubMed ID: 33667562
[TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
19. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
[TBL] [Abstract][Full Text] [Related]
20. Current management of advanced melanoma: a transformed landscape.
Gyorki DE; Spillane J; Speakman D; Shackleton M; Henderson MA
ANZ J Surg; 2014 Sep; 84(9):612-7. PubMed ID: 24842394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
